Specifically, combining ICIs with an adenovirus-based tumor antigen vaccine, an IL-15 superagonist (N-803), an anti-OX40/4-1BB, and docetaxel has demonstrated therapeutic benefits in both hot and cold tumor models, synergistically triggering an immune response169. This evidence concerns the gene IL15 and neoplasm.